Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Merger or Acquisition (June 2026)
8 slides from Standard Biotools's merger presentation, Jun 8, 2026
Slide 1: June 2026 Standard BioTools Announcement
June 2026 Standard BioTools Announcement
Slide 2: Today's Announcement: Merger with Treeline Biosciences
Today’s Announcement Merger with Treeline Biosciences Strategic Options for Our Businesses • Decision follows broad review of strategic and financial growth options after the Illumina transaction. • While the company has made strong progress since 2022, the current capital environment for small - ca
Slide 3: Treeline BioSciences Overview
Josh Bilenker , MD CEO and Co - Founder Loxo Oncology @ Lilly Loxo CEO and Founder VC, FDA, medical oncologist Jeff Engelman, MD, PhD CSO and Co - Founder Novartis Institutes for BioMedical Research MGH SABs of Loxo and Agios Founders Overview Treeline BioSciences 3 • Labs in Watertown, MA, San Dieg
Slide 4: Target Selection: Treeline's Four Criteria
Disease dependency Are we sure the target drives the disease? Therapeutic index Can we expect a wide gap between the beneficial dose and the poorly tolerated dose? Path to druggability Can we make a medicine that profoundly alters target function? Patient need & commercial potential If successful, w
Slide 5: What's Next?
Continue to operate as usual; no changes. Reiterate status quo and focus on continuity until closing. Send all external inquiries to Alex Kim, CFO Business As Usual Timing & Approvals Committed to Transparency Employee transition plans are top of mind as we work through Mass Cytometry and Microfluid
Slide 6: Questions?
Questions? 6
Slide 7: Forward-Looking Statements
7 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, among others, statements regarding the expected timing of the closing of the transaction; the potential benefits of the propo
Slide 8: Additional Information and Where to Find It
8 Additional Information and Where to Find It This presentation may be deemed to be solicitation material in respect of the proposed transaction involving Standard BioTools and Treeline . In connection with the proposed transaction and required stockholder approval, Standard BioTools intends to file
Standard BioTools — Merger or Acquisition (June 2026) on 6ix